Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors was written by Connelly, Stephen;Mortenson, David E.;Choi, Sungwook;Wilson, Ian A.;Powers, Evan T.;Kelly, Jeffery W.;Johnson, Steven M.. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2017.Quality Control of 2-(3-Bromophenyl)benzo[d]oxazole This article mentions the following:
Rate-limiting dissociation of the tetrameric protein transthyretin (TTR), followed by monomer misfolding and misassembly, appears to cause degenerative diseases in humans known as the transthyretin amyloidoses, based on human genetic, biochem. and pharmacol. evidence. Small mols. that bind to the generally unoccupied thyroxine binding pockets in the native TTR tetramer kinetically stabilize the tetramer, slowing subunit dissociation proportional to the extent that the mols. stabilize the native state over the dissociative transition state-thereby inhibiting amyloidogenesis. Herein, the authors use previously reported structure-activity relationship data to develop two semi-quant. algorithms for identifying the structures of potent and selective transthyretin kinetic stabilizers/amyloidogenesis inhibitors. The viability of these prediction algorithms, in particular the more robust in silico docking model, is perhaps best validated by the clin. success of tafamidis, the first-in-class drug approved in Europe, Japan, South America, and elsewhere for treating transthyretin aggregation-associated familial amyloid polyneuropathy. Tafamidis is also being evaluated in a fully-enrolled placebo-controlled clin. trial for its efficacy against TTR cardiomyopathy. These prediction algorithms will be useful for identifying second generation TTR kinetic stabilizers, should these be needed to ameliorate the central nervous system or ophthalmol. pathol. caused by TTR aggregation in organs not accessed by oral tafamidis administration. In the experiment, the researchers used many compounds, for example, 2-(3-Bromophenyl)benzo[d]oxazole (cas: 99586-31-9Quality Control of 2-(3-Bromophenyl)benzo[d]oxazole).
2-(3-Bromophenyl)benzo[d]oxazole (cas: 99586-31-9) belongs to benzoxazole derivatives. Benzoxazoles belong to the group of well-known antifungal agents with antioxidant, antiallergic, antitumoral and antiparasitic activity. The wide range in therapeutic potential of benzoxazole derivatives is related to the favourable interactions of the benzoxazole moiety with different protein targets.Quality Control of 2-(3-Bromophenyl)benzo[d]oxazole
Referemce:
Benzoxazole – Wikipedia,
Benzoxazole | C7H5NO – PubChem